Company Overview and News

Blackstone weighs sale of Thomson Reuters unit

2018-09-26 - 1
Blackstone is buying 55% of Refinitiv for US$17bil with co-investors Canada Pension Plan Investment Board and GIC Pte, Singapore’s sovereign wealth fund. The deal, slated to close on Oct 1, is Blackstone’s largest since financial crisis.

MOVES-Blockchain hires Jamie Selway to ramp up institutional business

2018-08-01 reuters
NEW YORK (Reuters) - Blockchain, one of the world’s biggest cryptocurrency wallet companies, said on Wednesday it had hired Jamie Selway, an electronic trading veteran and expert on U.S. equity market structure, as global head of institutional markets.

Buy Nasdaq For Dividend Growth

2018-07-23 seekingalpha
As I have previously written, I am an investor for long-term dividend income. I am willing to take a lower dividend yield now for a company that has potential for explosive dividend growth in the future. Nasdaq (NASDAQ: NDAQ) is a fundamentally sound lower risk company that is growing its dividends at a very nice pace. For long-term dividend growth, the Nasdaq could be the right choice to add to your portfolio for diversification and income.

CBOE: Buy This Trading King

2018-07-13 seekingalpha
The Momentum Growth Quotient for the company is 12.80, which is 24.5% higher than the average for the S&P 100.

Cboe Global Markets' (CBOE) CEO Ed Tilly on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Cboe Global Markets, Inc. (NASDAQ:CBOE) Q1 2018 Earnings Conference Call May 4, 2018 8:30 AM ET

JP Morgan: Sell Cboe stock because of slowing popularity

2018-03-21 cnbc
A slowdown in VIX futures trading will weigh on shares of Cboe Global Markets, J.P. Morgan warned clients Wednesday as it downgraded shares of the international exchange operator.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BATS / Bats Global Markets, Inc. on message board site Silicon Investor.

WIRX u003cthe old BATS u003e WIRX u003cthe old BATS u003e WIRX u003cthe old BATS u003e BATS about Batteries Batteries, Inc. BATS about Batteries Batteries, Inc. BATS about Batteries Batteries, Inc.
CUSIP: 05491G109